Faculty & Staff Details
 |
Name: | Ulrich Bickel |
| Position: | Professor | |
| Email: | ulrich.bickel@ttuhsc.edu | |
| Bio | Ulrich Bickel, M.D., graduated from the Medical School at the University of Ulm (Germany) in 1984 and completed a specialization in Clinical Pharmacology in 1991 (Benjamin-Franklin Hospital of the Free University of Berlin, Germany). After a period as postdoc in the Department of Medicine and Brain Research Institute at the University of California, Los Angeles (1991-1994), he pursued his academic career at Philipps-University of Marburg, Germany (1994-1999). Dr. Bickel joined the faculty in the Department of Pharmaceutical Sciences in 1999. His research focuses on novel strategies for drug delivery to the brain using physiological transport mechanisms at the blood-brain barrier. He has recently obtained funding from the National Multiple Sclerosis Soci |
Education:
1977 - 1984 Medical School at the University of Ulm, Germany.
1985 Dissertation (Dr. med.) at the University of Ulm.
1984 - 1991 Resident in Clinical Pharmacology and Postdoctoral Research Assistant, Institute of Clinical Pharmacology Benjamin Franklin Hospital of the Free University of Berlin (Germany).
1986 - 1988 Resident in Internal Medicine (Endocrinology) at Benjamin Franklin Hospital, Berlin
1991 - 1994 Postdoctoral researcher
Research Interests:
Drug delivery of protein drugs and antisense oligonucleotides
Transport mechanisms at the blood-brain barrier
Inflammatory reactions at the blood-brain barrier as therapeutic targets in neuroinflammatory disease (Multiple Sclerosis) and brain ischemia.
Recent Funding:
2003-2006 "Targeting the Blood-Brain Barrier in Neuroinflammation". National Institute of Neurological Disorders and Stroke
Publications:
Osburg B., Peiser C., Schomburg L., Doemling D., Ko Y.T., Voigt K., and Bickel U., Effect of Endotoxin on Expression of TNF receptors and Transport of TNFa at the Blood-Brain Barrier of the Rat. Am. J. Physiol. 283:E899-908, 2002.
Kunath K., von Harpe A., Petersen H., Fischer D., Voigt K., Kissel T., and Bickel U., The structure of PEG-Modified Poly(ethylene imines) Influences Biodistribution and Pharmacokinetics of their Complexes with NF-k B Decoy in Mice. Pharm. Res. 19: 810-817, 2002
Born J., Lange T., Kern W., McGregor G.P., Bickel U., and Fehm H.L., Sniffing Neuropeptides - A Transnasal Approach to the Human Brain. Nature Neurosci. 5: 514-516, 2002
Lynch N.J., Schneider H., Sim R.B., Bickel U., Schwaeble W.J. In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. Int. Immunopharmacol. 2: 415-422, 2002
Fehm H.L., Smolnik R., Kern W., McGregor G.P., Bickel U., Born J. The melanocortin melanocyte-stimulating hormone/ adrenocorticotropin(4-10) decreases body fat in humans. J. Clin. Endocrinol. Metab. 86: 1144-1148, 2001
Kang, Y.S., Voigt, K., and Bickel, U. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells. J. Drug Target. 8: 425-434, 2000
Lee, H. J., Engelhardt, B., Lesley, J., Bickel U., and Pardridge, W.M. Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse. J. Pharmacol. Exp. Ther. 252: 1048-1052, 2000
Bachus, R., Bickel U., Thomsen T., Roots, I., and Kewitz H. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 9: 661-668, 1999
Heitmann, J., Cassel, W., Grote L., Bickel, U., Hartlaub, U., Penzel, T., and Peter, J.H. Does short term treatment with Modafinil affect blood pressure in patients with obstructive sleep apnea? Clin. Pharmacol. Ther. 65: 328-335, 1999
Bickel, U., Grave, B., Kang, Y.S., del Rey, A. and Voigt, K. No increase in blood-brain barrier permeability after intraperitoneal injection of endotoxin in the rat. J. Neuroimmunol. 85: 131-136, 1998
Wu, D., Kang, Y.S., Bickel, U., and Pardridge, W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared to morphine. Drug Metabol. Dispos. 25: 768-771, 1997
Pardridge, W.M., Golden, P.L., Kang, Y.S., and Bickel, U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 68: 1278-1285, 1997
Bickel, U., Schumacher, O.P., Kang, Y.S., and Voigt, K. Poor permeability of morphine-3-glucuronide and morphine-6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278: 107-113, 1996
Bickel, U., Kang, Y.S., and Pardridge, W.M. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. Bioconjugate Chem. 6: 211-218, 1995
Bickel, U., Lee, V.M.Y., and Pardridge, W.M. Pharmacokinetic differences between 111In- and 125I-labeled cationized monoclonal antibody against ß-amyloid in mouse and dog. Drug Delivery 2: 128-135, 1995
Pardridge, W.M., Bickel, U., Buciak, J., Yang, J., Diagne, A., and Aepinus, C. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. Immunol. Lett. 42: 191-195, 1994
Bickel, U., Kang, Y.S., Yoshikawa, T., and Pardridge, W.M. In vivo demonstration of sub-cellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate within brain capillary endothelium. J. Histochem. Cytochem. 42: 1493-1497, 1994
Samii, A., Bickel, U., Stroth, U., and Pardridge, W.M. Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphin analogue. Am. J. Physiol. 267: E124-E131, 1994
Bickel, U., Lee, V.M.Y., Trojanowski, J.Q., and Pardridge, W.M. Development and in vitro characterization of a cationized monoclonal antibody against ßA4 protein: a potential probe for Alzheimer's disease. Bioconjugate Chem. 5: 119-125, 1994
Bickel, U., Yamada, S., and Pardridge, W.M. Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery. J. Pharmacol. Exp. Ther. 268: 791-796, 1994
Kang, Y.S., Bickel, U., and Pardridge, W.M. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metabol. Dispos. 22: 99-105, 1994
Pardridge, W.M., Bickel, U., Buciak, J., Yang, J., and Diagne, A. Enhanced endocytosis and anti-HIV activity of anti-rev antibodies following cationization. J. Infect. Dis. 164:55-61, 1994
Bickel, U., Yoshikawa, T., Landaw, E.M., Faull, K.F., and Pardridge, W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 90: 2618-2622, 1993
Gramm, H.J., Meinhold, H., Bickel, U., Zimmermann, J., von Hammerstein, B., Keller, F., Dennhardt, R., and Voigt, K. Acute endocrine failure after brain death? Transplantation 54: 851-857, 1992
Kunzendorf, U., Brockmoller, J., Bickel, U., Jochimsen, F., Walz, G., Roots, I., and Offermann, G. Promotion of B cell stimulation in graft recipients through a mechanism distinct from interleukin-6 gene superinduction. Transplantation 51: 1312-1315, 1991
Thomsen, T., Kaden, B., Fischer, J.P., Bickel, U., Barz, H., Gusztony, G., Cervos-Navarro, J., and Kewitz, H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 29: 487-492, 1991
Bickel, U., Thomsen, T., Weber, W., Fischer, J.P., Bachus, R., Nitz, M., and Kewitz, H. Pharmacokinetics of galanthamine in man and corresponding cholinesterase inhibition. Clin. Pharmacol. Ther. 50: 420-428, 1991
Bickel, U., Thomsen, T., Fischer, J.P., and Kewitz, H. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30: 447-454, 1991
Bickel, U. and Kewitz, H. Co-localization of choline acetyl-transferase and nerve growth factor receptor in the rat basal forebrain. Dementia 1: 146-150, 1991
Bickel, U., Wiegand-Löhnert, C., Fleischmann, J.W., Heinemeyer, G., Kewitz, H., Dennhardt, R., and Voigt, K. Different modulation of the perioperative stress hormone.